Gedatolisib, an innovative investigational treatment, has garnered attention following the FDA’s acceptance of its New Drug Application (NDA) for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA wild-type advanced breast cancer. This significant milestone, announced in a recent news release, sets a Prescription Drug User Fee Act (PDUFA) goal date of July 17, 2026, highlighting the urgency and importance of addressing this prevalent cancer subtype.
Understanding HR+/HER2- Breast Cancer
The HR+/HER2- subtype represents the majority of breast cancer cases, accounting for about two-thirds of all instances. Despite advancements in treatment options such as endocrine therapies and CDK4/6 inhibitors, a substantial number of patients develop resistance over time. This results in disease progression and a narrowing of effective treatment options, particularly for those with PIK3CA wild-type tumors.
The Significance of PIK3CA Wild-Type Status
The term “wild-type” refers to genes in their unmutated, natural form. In the context of breast cancer, mutations in genes like PIK3CA can dictate treatment pathways. Identifying whether a tumor is PIK3CA wild-type or mutated is vital, as many targeted therapies are designed to act on specific mutations. Approximately 60% of patients with HR+/HER2- advanced breast cancer fall into the wild-type category, illustrating a significant unmet medical need, as current therapies mainly target mutated forms.
The Path to FDA Acceptance
Celcuity submitted the NDA for gedatolisib under the FDA’s Real-Time Oncology Review (RTOR) program, enabling a more expedited examination of key efficacy and safety data even before the completion of the full application. This approach aims to enhance the efficiency of the drug approval process while maintaining rigorous standards. Gedatolisib has also been designated as a Breakthrough Therapy and received Fast Track status, emphasizing its potential to significantly benefit patients compared to existing treatments.
Clinical Evidence Supporting Gedatolisib
The NDA submission is bolstered by findings from the PIK3CA wild-type cohort of Celcuity’s Phase 3 VIKTORIA-1 clinical trial. This trial assessed the efficacy of gedatolisib in combination with fulvestrant, with or without palbociclib, in patients diagnosed with HR+/HER2- advanced breast cancer. Results from this cohort revealed clinically meaningful activity, reinforcing the drug’s potential to address a therapeutic gap for individuals with limited options following endocrine resistance.
Mechanism of Action
Gedatolisib functions as a multi-target inhibitor of the PI3K/AKT/mTOR (PAM) signaling pathway, a crucial driver of tumor growth and treatment resistance in breast cancer. Unlike traditional therapies that inhibit only one aspect of this pathway, gedatolisib targets all four Class I PI3K isoforms along with both mTOR complexes, mTORC1 and mTORC2. This comprehensive approach aims to diminish compensatory signaling, which can undermine the efficacy of single-target inhibitors.
Broad Activity Across Tumor Types
Early clinical and nonclinical studies indicate that gedatolisib possesses comparable potency and cytotoxic effects in both PIK3CA-mutant and PIK3CA wild-type breast cancer cells. This broad-spectrum activity sets gedatolisib apart from existing PI3K-pathway inhibitors, positioning it as a potentially relevant treatment for a larger segment of the HR+/HER2- breast cancer population.
Industry Perspective
Brian Sullivan, CEO and co-founder of Celcuity, expressed optimism regarding the FDA’s acceptance of the NDA for gedatolisib, describing it as a pivotal moment in the quest to provide a new treatment avenue for patients with HR+/HER2- advanced breast cancer. He emphasized that the comprehensive clinical dataset supporting the submission showcases the drug’s game-changing potential. The company looks forward to partnering with the FDA throughout the review process to achieve potential approval and market launch.
Conclusion
The acceptance of gedatolisib’s NDA by the FDA marks a promising development in the fight against advanced breast cancer, particularly for patients with the challenging HR+/HER2- PIK3CA wild-type subtype. As the review process unfolds, the potential for this multi-target therapy to transform treatment outcomes remains a beacon of hope for many. Continued advancements in cancer therapeutics like gedatolisib are essential to improving patient care and expanding the arsenal against this formidable disease.
- Gedatolisib targets both mutated and wild-type PIK3CA, broadening its potential patient base.
- The FDA’s acceptance reflects a commitment to expedite access to promising oncology treatments.
- Ongoing clinical trials continue to evaluate the therapeutic efficacy of gedatolisib in advanced breast cancer.
- Collaboration with regulatory bodies will be crucial for the future success of gedatolisib in the market.
Read more → www.managedhealthcareexecutive.com